WP
TRML

Woodline Partners’s Tourmaline Bio TRML Stock Holding History

Woodline Partners’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-85,177
Closed -$1.36M – 1051
2025
Q2 		$1.36M Sell
85,177
-74,909
-47% -$1.21M 0.01% 773
2025
Q1 		$2.43M Sell
160,086
-1,635
-1% -$26.2K 0.02% 637
2024
Q4 		$3.28M Buy
161,721
+2,567
+2% +$64.6K 0.02% 570
2024
Q3 		$4.09M Buy
159,154
+1,207
+0.8% +$20.1K 0.03% 410
2024
Q2 		$2.03M Buy
157,947
+588
+0.4% +$9.46K 0.02% 413
2024
Q1 		$3.6M Buy
+157,359
New +$5.55M 0.03% 392
2022
Q3 		– Sell
-20,606
Closed -$929K – 820
2022
Q2 		$929K Hold
20,606
– – 0.01% 525
2022
Q1 		$2.03M Hold
20,606
– – 0.03% 375
2021
Q4 		$3.15M Hold
20,606
– – 0.05% 351
2021
Q3 		$2.79M Sell
20,606
-10
-0% -$1.37K 0.05% 358
2021
Q2 		$3.03M Buy
+20,616
New +$3.16M 0.06% 292

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Woodline Partners's TRML Position: Q3 2025 in Review

Woodline Partners sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 85,177 shares — an estimated $1.36M sold.

Woodline Partners first reported a position in TRML in Q2 2021 and held it in 11 quarters. The position peaked at $4.09M in Q3 2024. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Woodline Partners reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 85,177 Tourmaline Bio shares in Q3 2025, an estimated $1.36M.
  • Woodline Partners first reported a position in Tourmaline Bio in Q2 2021 and held it in 11 quarters.
  • Woodline Partners's Tourmaline Bio position peaked at $4.09M in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.